Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
MabCure signs clinical research agreement to diagnose ovarian cancer

MabCure signs clinical research agreement to diagnose ovarian cancer

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

Significant opportunity for alternative ulcerative colitis biological therapy

Significant opportunity for alternative ulcerative colitis biological therapy

Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics signs contract to complete the final development of Anthim

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

iCo Therapeutics grants 725,000 stock options to directors, officers and employees

Phase 3 trial of figitumumab discontinued by Pfizer

Phase 3 trial of figitumumab discontinued by Pfizer

Affomix to generate antibodies against proprietary targets chosen by Kalgene

Affomix to generate antibodies against proprietary targets chosen by Kalgene

Promising results from Soligenix' RiVax vaccine against ricin toxin

Promising results from Soligenix' RiVax vaccine against ricin toxin

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Elusys Therapeutics receives contract to speed up drug development for Anthrax

Elusys Therapeutics receives contract to speed up drug development for Anthrax

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Viron Therapeutics' three drug candidates granted U.S. patents

Viron Therapeutics' three drug candidates granted U.S. patents

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

PDL BioPharma enters into non-exclusive license agreement with Eli Lilly

Seattle Genetics and GSK sign ADC collaboration agreement

Seattle Genetics and GSK sign ADC collaboration agreement

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.